Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485766 | 0.80 | EPHX2 (0.40) | MLYCDCA12CA14TSHRCYP2D6 | |
| SCHEMBL3929481 | 0.80 | GAA (0.42) | MLYCDTSHRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL27592388 | 0.78 | MLYCD (0.35) | MLYCDCYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL948359 | 0.78 | PAOX (0.38) | MLYCDCA12CA14CYP2D6GAA | |
| SCHEMBL16024112 | 0.77 | EGLN1 (0.43) | MLYCDTSHRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL8157293 | 0.75 | LMNA (0.52) | TSHRALDH1A1 | |
| SCHEMBL948270 | 0.75 | EPHX2 (0.37) | MLYCDCA12CA14TSHRCYP2D6 | |
| SCHEMBL10546688 | 0.75 | ALDH1A1 (0.36) | MLYCDCYP1A2CYP2D6CYP2C19MGAM | |
| SCHEMBL3666005 | 0.75 | CA12 (0.42) | CA12CA14TSHRGAAALDH1A1 | |
| SCHEMBL3929483 | 0.74 | CYP2D6 (0.35) | MLYCDTSHRCYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257249-A1 | DRUG CARRIERS | NITTO DENKO CORPORATION (JP) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257249-A1 | DRUG CARRIERS | HDGF, FIBP, SLC47A2 | MLYCD 2671/4885CA12 1387/4885CA14 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.